tadekinig alfa
Recombinant proteinexperimental
Clinical trial activity
4 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
3
Phase 3
2
Phase 4
0
Earliest trial started Feb 1, 2015 (NCT02398435)
Timeline
Indications
Mechanism of action
- Interleukin-18INHIBITOR
Interleukin-18 inhibitor
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2108054 ↗
Also known as
- il-18 binding protein
- tadekinig alfa
- tadekinig alfa
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05306080 | Early Phase 1 (Phase 1) | Apr 17, 2022 | University of Pennsylvania |
| NCT03512314 | Phase 3 | Jan 24, 2018 | AB2 Bio Ltd., University of Pennsylvania |
| NCT03113760 | Phase 3 | May 15, 2017 | AB2 Bio Ltd., University of Pennsylvania |
| NCT02398435 | Phase 2 | Feb 1, 2015 | AB2 Bio Ltd., University of Geneva |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AB2 Bio Ltd. | For profit | 3 | 3 | 2 | 2015 |
| University of Pennsylvania | Academic/Hospital | 3 | 1 | 2 | 2017 |
| University of Geneva | Academic/Hospital | 1 | 0 | 1 | 2015 |
3 organizations
Page 1 / 1